Patents Issued in June 13, 2017
  • Patent number: 9675631
    Abstract: One aspect of the present invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating a proliferative disorder, wherein the sapacitabine or metabolite thereof is administered in a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle comprises administering a therapeutically effective amount of sapacitabine or metabolite thereof for about 2 to about 6 days per week, for 2 weeks out of 3 weeks. Another aspect of the invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating cutaneous T-cell lymphoma (CTCL).
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: June 13, 2017
    Assignee: Cyclacel Limited
    Inventor: Judy H. Chiao
  • Patent number: 9675632
    Abstract: The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: June 13, 2017
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yao-Ling Qiu, Xiaowen Peng, Xuri Gao, Hui Cao, Yat Sun Or
  • Patent number: 9675633
    Abstract: In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Amy Heimberger, Jun Wei
  • Patent number: 9675634
    Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 13, 2017
    Assignee: Vtesse Inc.
    Inventors: Bernardus Nicolaas Machielse, Allan Darling
  • Patent number: 9675635
    Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments and glucosamine in an oral dosage form.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 13, 2017
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Patent number: 9675636
    Abstract: A polymer composition for sequestering lipid-bile acid micelles in the gastrointestinal (GI) tract is provided. The polymer composition comprises a copolymer of a pH-sensitive monomer and one or more of positively-charged monomers. The polymer composition is able to bind micelles under various physiological conditions in the GI tract and possesses the ability to flocculate the bound micelle upon exposure to a particular pH. The flocculation of the polymer:micelle complex prevents absorption of the micelle thereby causing the polymer:micelle complex to be eliminated with the fecal matter. Thus, the polymer composition described herein may be effective in reducing cholesterol, bile acid, and/or triglyceride levels and promote weight loss.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Cory Berkland, Jian Qian, Bradley Paul Sullivan
  • Patent number: 9675637
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: June 13, 2017
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting through Louisiana State University Health Sciences Center, The UAB Research Foundation, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Patent number: 9675638
    Abstract: The present invention comprises the use of a therapeutically effective amount of a tungsten (VI) salt with a pharmaceutically or veterinarily acceptable cationic group, or a solvate of said salt, for the preparation of a medicinal product for the treatment of female infertility in non-diabetic mammals.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: June 13, 2017
    Assignee: OXOLIFE, S.L.
    Inventors: Ignacio Canals Almazán, Agnès Arbat Bugié
  • Patent number: 9675639
    Abstract: Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: June 13, 2017
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Stuart D. Shanler, Christopher Powala, Christopher Phillips, Brian Beger, Charles Rodney Greenaway Evans, Sian Tiong Lim, Marc Barry Brown, Michael A. Botta, Thomas Nagler
  • Patent number: 9675640
    Abstract: Magnetic calcium phosphate particles are provided including particles comprising iron oxide and calcium phosphate. A chitosan coating is present on the particles, wherein the particles are less than or equal to 1,000 nm, are magnetic and exhibit a positive charge in the range of 1 mVolts to 60 mVolts. The particles are provided by preparing a calcium hydroxide solution and filtering the calcium hydroxide solution in a membrane filter. An iron chloride solution is formed and combined with the filtered calcium hydroxide solution. In addition, the phosphoric acid solution is combined with the combined solutions of iron chloride and calcium hydroxide, forming a mixture including particles comprising iron oxide and calcium phosphate.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: June 13, 2017
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Xingguo Cheng, Qingwen Ni, Thomas B. Potter
  • Patent number: 9675641
    Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 13, 2017
    Assignee: Indiana University Research & Technology Corporation
    Inventors: Louis M. Pelus, Jonathan Hoggatt, Pratibha Singh
  • Patent number: 9675642
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: June 13, 2017
    Assignees: University Of Pittsburgh—Of The Commonwealth System Of Higher Education, Intrexon Corporation
    Inventors: J. Mark Braughler, Prasanna Kumar, Walter J Storkus, Hideho Okada
  • Patent number: 9675643
    Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture is compatible with biologic function.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: June 13, 2017
    Assignee: Vivex Biomedical, Inc.
    Inventors: Wendy W. Weston, Miguel Quevedo, Stuart Oglesby, Gaëtan Jean-Robert Delcroix, Paul C. Schiller, Gianluca D'Ippolito, Timothy Ganey
  • Patent number: 9675644
    Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture is compatible with biologic function.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: June 13, 2017
    Assignee: Vivex Biomedical, Inc.
    Inventors: Wendy W. Weston, Miguel Quevedo, Stuart Oglesby, Gaëtan Jean-Robert Delcroix, Paul C. Schiller, Gianluca D'Ippolito, Timothy Ganey
  • Patent number: 9675645
    Abstract: Methods for increasing osteoinductivity and/or surface area of bone material are provided. The methods include providing bone material and dehydrating the bone material with a solvent at its critical point. A useful solvent for critical point dehydrating is carbon dioxide. Critical point dehydration resulting in increased osteoinductivity and/or surface area can be applied to many types of bone material including bone particles, bone chips, bone fibers, bone matrices, both demineralized and non-demineralized. An implantable composition having an enhanced osteoinductivity and/or osteoconductivity is also provided. The implantable composition contains demineralized bone matrix dried at critical point of carbon dioxide. Critical point dried fibers of a demineralized bone matrix have a BET value from about 40 m2/gm to about 100 m2/gm, a value that is 100 times higher than corresponding vacuum dried or lyophilized DBM fibers.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: June 13, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Guobao Wei
  • Patent number: 9675646
    Abstract: Methods of generating tubular, bioengineered, smooth muscle structures are disclosed as well as bioengineered tissue for tubular organ repair or replacement. The methods can include the steps of obtaining smooth muscle cells; culturing the muscle cells to form a smooth muscle cell construct of directionally oriented smooth muscle cells; disposing the smooth muscle cell construct around a tubular scaffold; and culturing construct and scaffold in a growth media until a smooth muscle cell structure is achieved. The step of obtain smooth muscle cells can further include obtaining autologous smooth muscle cells from a subject. In one preferred embodiment, the muscle cells can first be on a fibrin substrate to form a muscle construct, which is then disposed around a tubular scaffold, for example, a chitosan scaffold. The methods of the present invention can further include connecting two or more tubular structures together to form an elongate composite structure.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: June 13, 2017
    Assignee: Wake Forest University Health Sciences
    Inventor: Khalil Bitar
  • Patent number: 9675647
    Abstract: The present inventors conducted dedicated studies, and as a result discovered that propionic acid bacteria fermentation products have a preventive/therapeutic effect on functional gastrointestinal disorders in in vitro tests and tests using patients with irritable bowel syndrome, and completed the present invention. Specifically, the present inventors discovered, in in vitro tests, that the products have an effect of increasing the intestinal contraction frequency without changing the intestinal contractile force in a distal colon-specific manner. Moreover, effects of improving the defecation condition, general abdominal condition, and health-related QOL in patients with irritable bowel syndrome were also found. Furthermore, propionic acid bacteria fermentation products can be taken in large amounts. Therefore, the propionic acid bacteria fermentation products can be expected to have an effect of preventing/treating functional gastrointestinal disorders safely.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: June 13, 2017
    Assignee: MEIJI CO., LTD.
    Inventors: Masayuki Uchida, Shigeru Yamato, Hajime Ariga, Hirotsugu Uehara, Tomofumi Amano, Keiko Morikubo, Kaori Yoshida
  • Patent number: 9675648
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: June 13, 2017
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
  • Patent number: 9675649
    Abstract: The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: June 13, 2017
    Assignee: The Regents of the University of California
    Inventor: Lars Bode
  • Patent number: 9675650
    Abstract: The present invention relates to a composition for removing keratinous skin material, the composition comprising a Lactobacillus strain or a culture thereof. Also, the present invention relates to a composition for removing keratinous skin material, the composition comprising green tea Lactobacillus as Lactobacillus. In contrast to when skin is improved through the supply of a moisture fraction by a commonly used skin-moisturizing component, the Lactobacillus according to the present invention removes keratinous skin material, thereby producing the advantageous effect that skin can be cared for and improved as the waste materials which accumulates on the skin is fundamentally removed. Therefore, the composition according to the present invention can effectively prevent or alleviate skin problems such as spots. Also, the invention regulates the skin and so improves skin tone by removing surplus keratinous material which is not needed by the skin.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: June 13, 2017
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Joon Ho Park, Yeon Ju Hong, Il Young Kwack, Jong Won Shim, Jin Sup Shim, Kyeong Hwan Hwang, Young Gyu Kang, Myeong Hun Yeom, Jun Cheol Cho
  • Patent number: 9675651
    Abstract: Methods and compositions for increasing intestinal transport of nutrients or growth performance in the offspring of an animal are described. More specifically, a feed composition comprising an omega-3 fatty acid-containing composition for increasing intestinal transport of nutrients or growth performance in the offspring of the animal, and methods therefor, are described.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 13, 2017
    Assignee: JBS UNITED, INC.
    Inventor: Joel Dean Spencer
  • Patent number: 9675652
    Abstract: Compounds having unique properties are prepared from the herbal compositions described herein and comprise extracts derived from plants and fungi of the genera Panax, Ganoderma, and Saussurea. The compositions are useful in preventing, treating, relieving, and improving the quality-of-life of patients suffering from chronic diseases, such as liver diseases, cancer, cachexia, and immune system disorders.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: June 13, 2017
    Assignee: HXLS Charity Corp.
    Inventor: Andy Teh-An Huang
  • Patent number: 9675653
    Abstract: A composition useful for maintaining healthy levels of testosterone in men and women. The composition includes essential oils from a tree of the genus Picea or a product of this oil. The essential oil product can specifically come from essential oil from the plant Picea pungens, commonly referred to as Blue Spruce. Also disclosed is a method for maintaining healthy levels of testosterone in men and women utilizing the composition. In some implementations, the composition is a pharmaceutical composition that further includes a penetration enhancer. A method for utilizing the pharmaceutical composition for treating hypogonadism is also disclosed.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: June 13, 2017
    Assignee: Young Living Essential Oils, LC
    Inventor: D. Gary Young
  • Patent number: 9675654
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 13, 2017
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borrelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Patent number: 9675655
    Abstract: The present invention relates to compositions comprising black cumin (Nigelia sativa seed) oil, olive oil, tea tree (Melaleuca alternifolia) oil, cocoa butter, vitamin A or a derivative thereof, and vitamin B12 or a derivative thereof. The compositions of the present invention can be advantageously used in the in the treatment of dermatological conditions, disorders or diseases, in particular inflammatory dermatological diseases such as psoriasis.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: June 13, 2017
    Assignee: Veit Hoermann Gesellschaft Für Unternehmenskommunikation mbH
    Inventor: Thaher Kamal
  • Patent number: 9675656
    Abstract: A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 13, 2017
    Inventor: Kenneth L Crowley
  • Patent number: 9675657
    Abstract: According to this invention there is provided a herbal formulation for the prevention and management of neurodegenerative disorders comprising, hydro-methanolic extract of at least one plant selected from Curcuma longa, Bacopa monnieri and Valeriana jatamansi, at 70-80° C., maintaining the pH of the solution between 7-10, Separating the active compounds chromatographically and Subjecting the active compounds to the step of molecular characterization.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: June 13, 2017
    Assignee: SRM UNIVERSITY
    Inventors: Govind Prasad Dubey, Aruna Agrawal, Nirupama Dubey, Shipra Dubey, Rajesh Dubey, Samathanam Mercy Deborah
  • Patent number: 9675658
    Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.
    Type: Grant
    Filed: September 11, 2016
    Date of Patent: June 13, 2017
    Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
  • Patent number: 9675659
    Abstract: Methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: June 13, 2017
    Assignee: Trilogy Therapeutics, Inc.
    Inventors: David M. Ryckman, Iching G. Yu
  • Patent number: 9675660
    Abstract: The present invention relates to peptides for inhibiting angiogenesis. The present invention also relates to methods of inhibiting angiogenesis and methods of treating disorders associated with VEGF-induced vascular permeability using the peptides of the invention.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 13, 2017
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Yulia A. Komarova, Mark Rosenblatt, Asrar B. Malik
  • Patent number: 9675661
    Abstract: Peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are described.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 13, 2017
    Assignee: AILERON THERAPEUTICS, INC.
    Inventor: Huw M. Nash
  • Patent number: 9675662
    Abstract: Compositions for inhibition of RNA Polymerase I include peptides of Rpa43. Methods of production and use thereof are also disclosed.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 13, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Lawrence Rothblum
  • Patent number: 9675663
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: June 13, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack Roth, David Stewart, Charles Lu, Ignacio I. Wistuba, Shaoyu Yan, Maria I. Nunez
  • Patent number: 9675664
    Abstract: This invention discloses a method of and composition for treating a PE-type disorder in a subject in need of such treatment comprising administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a TTR polypeptide in admixture with a pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: June 13, 2017
    Assignee: Brown University
    Inventors: Surendra Sharma, Satyan Kalkunte, Udo Markert
  • Patent number: 9675665
    Abstract: A method of treating or preventing a gum disease or gum disorder or gum injury in a mammal by administering to the mammal at least one inflammation modulatory or anti-inflammatory protein or polypeptide, such as TSG-6 protein, or a biologically active fragment, derivative, or analogue thereof. Gum diseases or gum disorders or gum injuries that may be treated include periodontal gum disease, and gum wounds resulting from gum surgeries.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: June 13, 2017
    Assignee: The Texas A & M University System
    Inventors: Darwin J. Prockop, Kathy K. H. Svoboda, Stacy Renay Beltran
  • Patent number: 9675666
    Abstract: There are provided a tablet-form immediate-release preparation that contains a high concentration of a casein and/or a casein hydrolysate as an active ingredient but has an excellent physical strength, a composition for the preparation that has an excellent tabletability, and a method for producing the preparation from the composition. Each of the preparation and the composition contains 50% by mass or more of the casein and/or the casein hydrolysate, and further contains a lactose having a volume average particle diameter of not less than 50 ?m and not more than 300 ?m. The content of the lactose is 6.0 to 100 parts by mass per 100 parts by mass of the casein and/or the casein hydrolysate. The method for producing the preparation contains the steps of: preparing a mixture as the composition; filling a mortar with the mixture and tableting the mixture; and separating the tableted mixture from the mortar.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: June 13, 2017
    Assignee: ASAHI CALPIS WELLNESS CO., LTD.
    Inventor: Akira Kubota
  • Patent number: 9675667
    Abstract: A method of altering intercellular interactions between a combination of microorganisms includes contacting a combination of different species of microorganisms with at least one mucin. Isolated compositions include a combination of microorganisms and at least one mucin. One microorganism of the combination inhibits cell growth or promotes cell death of at least one other microorganism of a different species in the combination. The combination of microorganisms with the mucin results an increase in cell growth or a reduction in cell death, respectively, of the at least one other microorganism.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 13, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Katharina Ribbeck, Nicole Lynn Kavanaugh, Julia Yin-Ting Co, Erica Shapiro
  • Patent number: 9675668
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: June 13, 2017
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
  • Patent number: 9675669
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 13, 2017
    Assignee: HOBA THERAPEUTICS APS
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Patent number: 9675670
    Abstract: A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: June 13, 2017
    Assignee: Induce Biologics Inc.
    Inventors: Cameron M. L. Clokie, Sean A. F. Peel
  • Patent number: 9675671
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: June 13, 2017
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Patent number: 9675672
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. Also described are peptide antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple ?c-cytokine family members.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 13, 2017
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 9675673
    Abstract: Methods, apparatus and compositions are provided for treatment of cancer of a selected organ by intraluminal delivery of oncolytic agents through a blood vessel or duct leading to the cancer tissue. During the time the oncolytic agents are being applied to the targeted tissue downstream, the designated vessel or duct can be selectively occluded to increase concentration and pressure of the applied agents at the target site. Oncolytic compositions including oncolytic viruses formulated with delivery visualization markers are provided.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: June 13, 2017
    Assignee: INGENERON INCORPORATED
    Inventor: Eckhard U. Alt
  • Patent number: 9675674
    Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: June 13, 2017
    Assignee: MannKind Corporation
    Inventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
  • Patent number: 9675675
    Abstract: A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 13, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Ying Zhang, Percy T. Fenn, Peter R. Johnson
  • Patent number: 9675676
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 13, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Patent number: 9675677
    Abstract: The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization, and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: June 13, 2017
    Assignee: Boston Scientific Scimed, Inc.
    Inventor: Natalie Ann Borgos
  • Patent number: 9675678
    Abstract: Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: June 13, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Jan P Kraus, Tomas Majtan, Erez Bublil
  • Patent number: 9675679
    Abstract: The invention features immunoconjugates for impeding weight gain and treating obesity in a subject. The immuno-conjugates comprise particular ghrelin polypeptides and a suitable carrier moiety.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: June 13, 2017
    Assignee: The Scripps Research Institute
    Inventors: Eric P. Zorrilla, Michael M. Meijler, Kim D. Janda
  • Patent number: 9675680
    Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 13, 2017
    Assignee: OncoTherapy Science
    Inventors: Takuya Tsunoda, Ryuji Ohsawa